Frontiers in Pharmacology (Nov 2022)

Drug-induced liver injury in COVID-19 treatment: Incidence, mechanisms and clinical management

  • Xichuan Li,
  • Wanting Wang,
  • Wanting Wang,
  • Suying Yan,
  • Suying Yan,
  • Weipeng Zhao,
  • Hui Xiong,
  • Cuiping Bao,
  • Jinqian Chen,
  • Yuan Yue,
  • Yanjun Su,
  • Chunze Zhang

DOI
https://doi.org/10.3389/fphar.2022.1019487
Journal volume & issue
Vol. 13

Abstract

Read online

The COVID-19 outbreak triggered a serious and potentially lethal pandemic, resulting in massive health and economic losses worldwide. The most common clinical manifestations of COVID-19 patients are pneumonia and acute respiratory distress syndrome, with a variety of complications. Multiple organ failure and damage, ultimately leading to patient death, are possible as a result of medication combinations, and this is exemplified by DILI. We hope to summarize DILI caused by the antiviral drugs favipiravir, remdesivir, lopinavir/ritonavir, and hydroxychloroquine in COVID-19 patients in this review. The incidence of liver injury in the treatment of COVID-19 patients was searched on PubMed to investigate DILI cases. The cumulative prevalence of acute liver injury was 23.7% (16.1%–33.1%). We discuss the frequency of these events, potential mechanisms, and new insights into surveillance strategies. Furthermore, we also describe medication recommendations aimed at preserving DILI caused by treatment in COVID-19 patients.

Keywords